Outlook Therapeutics Seeks FDA Meeting on ONS-5010 BLA

An update from Outlook Therapeutics ( (OTLK) ) is now available.

On February 11, 2026, Outlook Therapeutics announced it had requested a Type A meeting with the U.S. Food and Drug Administration to address a Complete Response Letter dated December 30, 2025, relating to its resubmitted biologics license application for ONS-5010/LYTENAVA for wet age-related macular degeneration. The letter cited a single deficiency, a purported lack of substantial evidence of effectiveness and a need for additional confirmatory data, a conclusion the company disputes based on prior FDA interactions and the totality of its clinical package.

Outlook Therapeutics emphasized that its BLA is backed by the Phase 3 NORSE TWO trial, which met primary and key secondary visual acuity endpoints at 12 months, and by NORSE EIGHT and other mechanistic, pharmacodynamic and natural history data that it says collectively satisfy the FDA’s substantial evidence standard. While NORSE EIGHT did not meet its primary endpoint at eight weeks, the company highlighted consistent vision gains through 12 weeks, a favorable safety profile comparable to existing anti-VEGF therapies, and argued that an FDA-approved, domestically manufactured bevacizumab for wet AMD could offer a standardized, high-quality alternative to current off-label use, making the outcome of these regulatory discussions significant for patients, prescribers and the U.S. retina market.

The most recent analyst rating on (OTLK) stock is a Sell with a $0.38 price target. To see the full list of analyst forecasts on Outlook Therapeutics stock, see the OTLK Stock Forecast page.

Spark’s Take on OTLK Stock

According to Spark, TipRanks’ AI Analyst, OTLK is a Neutral.

Overall score is driven primarily by very weak financial performance (ongoing losses, negative equity, and sustained cash burn) and bearish technical trends (price below all major moving averages with negative MACD). Valuation provides limited support because the company is still loss-making and offers no dividend yield.

To see Spark’s full report on OTLK stock, click here.

More about Outlook Therapeutics

Outlook Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing ONS-5010/LYTENAVA, an ophthalmic formulation of bevacizumab for retinal diseases such as wet age-related macular degeneration. The company has begun commercial launches of LYTENAVA in Germany and the UK after securing marketing authorizations in the European Union and the UK, positioning it as the first authorized bevacizumab eye therapy in those markets.

In the United States, ONS-5010/LYTENAVA remains investigational as Outlook Therapeutics seeks regulatory approval that would make it the first FDA-approved ophthalmic bevacizumab for retinal indications. The product is supported by a fully domestic U.S. manufacturing supply chain, which the company highlights as enhancing supply reliability and aligning with broader public health and national resilience priorities.

Average Trading Volume: 7,090,229

Technical Sentiment Signal: Sell

Current Market Cap: $29.74M

For an in-depth examination of OTLK stock, go to TipRanks’ Overview page.